Bausch + Lomb Corp (BLCO) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Bausch + Lomb Corp stock (BLCO) is currently trading at $16.02. Bausch + Lomb Corp PS ratio (Price-to-Sales) is 1.09. Analyst consensus price target for BLCO is $18.46. WallStSmart rates BLCO as Underperform.
- BLCO PE ratio analysis and historical PE chart
- BLCO PS ratio (Price-to-Sales) history and trend
- BLCO intrinsic value — DCF, Graham Number, EPV models
- BLCO stock price prediction 2025 2026 2027 2028 2029 2030
- BLCO fair value vs current price
- BLCO insider transactions and insider buying
- Is BLCO undervalued or overvalued?
- Bausch + Lomb Corp financial analysis — revenue, earnings, cash flow
- BLCO Piotroski F-Score and Altman Z-Score
- BLCO analyst price target and Smart Rating
Bausch + Lomb Corp
📊 No data available
Try selecting a different time range
Smart Analysis
Bausch + Lomb Corp (BLCO) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in peg ratio, price/sales, price/book. Concerns around return on equity and eps growth. Mixed signals suggest waiting for clearer direction before acting.
Bausch + Lomb Corp (BLCO) Key Strengths (4)
Growing significantly faster than its price suggests
Trading below book value, meaning the market prices it less than net assets
Paying $1.09 for every $1 of annual revenue
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
Bausch + Lomb Corp (BLCO) Areas to Watch (6)
Company is destroying shareholder value
Earnings declining -88.60%, profits shrinking
Company is losing money with a negative profit margin
Very low institutional interest at 11.47%
Thin operating margins with cost pressures present
Modest revenue growth at 9.80%
Bausch + Lomb Corp (BLCO) Detailed Analysis Report
Overall Assessment
This company scores 47/100 in our Smart Analysis, earning a D+ grade. Out of 10 metrics analyzed, 4 register as strengths (avg 8.8/10) while 6 fall into concern territory (avg 1.7/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on PEG Ratio, Price/Book, Price/Sales. Valuation metrics including PEG Ratio (0.70), Price/Sales (1.09), Price/Book (0.86) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, EPS Growth, Profit Margin. Growth concerns include Revenue Growth at 9.80%, EPS Growth at -88.60%, which may limit upside. Profitability pressure is visible in Return on Equity at -5.39%, Operating Margin at 11.30%, Profit Margin at -7.06%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -5.39% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 9.80% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and EPS Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
BLCO Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
BLCO's Price-to-Sales ratio of 1.09x trades 20% below its historical average of 1.37x (13th percentile). The current valuation is 42% below its historical high of 1.89x set in Jun 2023, and 29% above its historical low of 0.85x in May 2025.
Compare BLCO with Competitors
Top MEDICAL INSTRUMENTS & SUPPLIES stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Bausch + Lomb Corp (BLCO) · HEALTHCARE › MEDICAL INSTRUMENTS & SUPPLIES
The Big Picture
Bausch + Lomb Corp is in a turnaround phase, with management focused on restoring profitability. Revenue reached 5.1B with 10% growth year-over-year. The company is currently unprofitable, posting a -7.1% profit margin.
Key Findings
Generating 62M in free cash flow and 134M in operating cash flow. Earnings are translating into actual cash generation.
The company is unprofitable with a -7.1% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Debt management: total debt of 5.4B is significantly higher than cash (383M). Monitor refinancing risk.
Sector dynamics: monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive moves, and regulatory changes that could impact Bausch + Lomb Corp.
Bottom Line
Bausch + Lomb Corp is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Bausch + Lomb Corp(BLCO)
NYSE
HEALTHCARE
MEDICAL INSTRUMENTS & SUPPLIES
USA
Bausch Lomb Corporation is an eye health company in Canada and internationally. The company is headquartered in Vaughan, Canada.